Drug intelligence / Profile preview

L49-Fab'-bL

Development stage
Preclinical
Lead developer
Bristol Myers Squibb
Modality
Immunotoxins → Antibody Conjugates → Antibody-Based Therapeutics, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration
Intravenous
01

Overview

**L49-Fab'-bL** is an experimental, chemically assembled antibody-enzyme conjugate developed for antibody-directed enzyme prodrug therapy. It comprises the Fab' fragment of the L49 monoclonal antibody, which recognizes the tumor-associated p97 antigen, also called melanotransferrin, covalently coupled through a heterobifunctional cross-linker to *Enterobacter cloacae* beta-lactamase. After tumor localization, the enzyme was intended to activate cephalosporin-containing anticancer prodrugs at antigen-positive tumor-cell surfaces. It was evaluated in preclinical melanoma, renal carcinoma, and lung carcinoma models as a chemically prepared comparator to the recombinant L49-sFv-bL fusion protein; no clinical development program, marketed product, or regulatory approval has been identified. ([europepmc.org](https://europepmc.org/article/MED/10563779))

Other names
L49-Fab'-bLL49-Fab′-bL
02

Targets

MELTF (Melanotransferrin)

Beyond the preview

Go deeper on L49-Fab'-bL.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on L49-Fab'-bL.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call